STAT

What we’ve learned about the coronavirus — and what we still need to know

As we approach the three-month mark of the spread of #coronavirus, the amount of information that’s been gained about it is staggering.
A man walks in a business district in Wuhan, where the coronavirus first emerged.

As we approach the three-month mark since we all learned about a new virus triggering serious respiratory infections in China, the amount of information that’s been gained about the new coronavirus is staggering.

In 2003, when SARS first emerged in China, it took weeks for laboratories to figure out what was causing new and sometimes deadly cases of pneumonia there and elsewhere.

This time, rumors of a possible new coronavirus were reported in China at the end of December, roughly the same time the country alerted the World Health Organization that it had a dangerous outbreak on its hands. By Jan. 10, the full genetic sequence of the virus had been shared with scientists around the globe.

The sharing of the sequence data has allowed countries around the world to ramp up testing for the virus, using laboratory-designed kits and scores of commercial tests now flooding the market. Those tests are critical to trying to lessen spread of the virus.

“The fact that so many tests are out there, the fact that there are so many testing platforms available now, is a remarkable success for science,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks